Leadership
Elliot Marseille, DrPH, MPP
Elliot Marseille is Principal of the firm, Health Strategies International. Trained in health policy analysis at the University of California, Berkeley, he has 40 years of senior public health management and research experience and has published widely on the economics of global health diseases and conditions, with a focus on HIV/AIDS.In addition to participating in the development of a wide range of global health cost and cost-effectiveness analyses, he is the Co-Course Director for Cost-Effectiveness Analysis in Medicine and Public Health, at UCSF. Additional interests include examination of the ethical foundations of cost-effectiveness analysis and identifying sound criteria for judging cost-effectiveness.
Dr. Marseille is also a leading expert on the economics of the emerging psychedelic-assisted therapies. He is the founding Director of the UCB / UCSF Collaborative for the Economics of Psychedelics (CEP), a network of health economists and health services researchers dedicated to realizing the potential of psychedelic therapies for high-priority mental health conditions. Through the application of policy-relevant economic analyses, CEP seeks to enhance the efficiency of service delivery and increase access to these promising therapies. Among CEP’s current projects are consultation with the Multidisciplinary Association for Psychedelic Studies (MAPS) in modeling the economics of MDMA-Assisted Therapy (MDMA-AT) for the treatment of PTSD; with the Usona Institute in analyzing the cost-effectiveness of psilocybin-assisted therapy for major depression; and with John Hopkins University on the cost-effectiveness of psilocybin-assisted therapy for tobacco cessation.
Additional projects now underway include the development of an economic model to assess the impact of ibogaine-assisted therapy for opioid use disorder, Reviewing the published literature on the health effects of the use of psychedelics in non-clinical settings, Modeling the epidemic and cost impact of making MDMA-assisted therapy for both military personnel and civilians in Ukraine.
James G, Kahn, MD, MPH
James G, Kahn, MD. MPH, is a global leader in cost-effectiveness analysis and other methods of economic appraisal of public health and clinical interventions. He has three decades of academic health policy research experience at the University of California San Francisco (where he is emeritus professor), at the Philip R. Lee Institute for Health Policy Studies, the Department of Epidemiology and Biostatistics, and the Institute for Global Health Sciences. His work focuses on the use of cost-effectiveness analysis to inform decision-making in public health and medicine. He is a widely published and cited expert in the economic assessment of HIV prevention and treatment programs and in a wide range of other global health issues.
Dr. Kahn also studies HIV prevention and care in the U.S.; has published cost-effectiveness analyses for other medical interventions; and is an authority on administrative costs in U.S. health care. He is the Co-PI of the Policy Program in the new Clinical Translational Sciences Institute at UCSF and has served as advisor and consultant to multiple U.S. and international agencies. Dr. Kahn has received approximately $20 million in funding from NIH, CDC, WHO, UNAIDS, the Bill and Melinda Gates Foundation, and other US and global agencies and foundations He has published nearly 200 peer reviewed articles and scores of reports and book chapters and served on several US Institute of Medicine review panels. Dr. Kahn has collaborated closely with Dr. Marseille for nearly 30 years and is a senior collaborator with Collaborative for the Economics of Psychedelics (CEP).
Stefano Bertozzi, MD, PhD
Stefano Bertozzi MD, PhD is a professor of health policy and management at the University of California, Berkeley School of Public Health, and the former dean of that school. Previously, he directed HIV and tuberculosis programs at the Bill & Melinda Gates Foundation. His research has covered a diverse range of projects in health economics and policy, focusing especially on the economic aspects of HIV/AIDS and on the health impact of large social programs. He oversaw the development of a new initiative in efficiency and effectiveness and represented the Private Foundations’ Constituency on the Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Dr. Bertozzi recently served as the interim director of Alianza UCMX, the newly-integrated UC systemwide programs with Mexico, and was the founding editor-in-chief for Rapid Reviews: COVID-19, an open-access overlay journal that accelerates peer review of COVID-19-related research preprints to advance new findings and prevent the dissemination of misleading scientific news. He co-edited the Disease Control Priorities (DCP3) volume on HIV/AIDS, Malaria & Tuberculosis. He serves or has served on many governance and advisory boards including UNICEF, WHO, UNAIDS, the Global Fund, PEPFAR, the NIH, Duke University, the International Partnership for Microbicides, and the AMA. He is a member of the National Academy of Medicine and was the last director of the WHO Global Programme on AIDS, and the founding director of the Center for Evaluation and Surveys at the Instituto Nacional de Salud Pública in México. He has also held positions with UNAIDS, the World Bank and the Government of the DRC. His work on economic evaluation has included many areas, but the current inclusion of the economic evaluation of pharmacological treatment for mental illness is recent, and results from his long-standing collaboration with Dr. Elliot Marseille.